Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control

 
• By Sten Stovall
  
ScienceLab
Tizona and AbbVie hope to develop and commercialize CD39-targeted therapeutics • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip